The c-MET inhibitor PF-2341066 suppresses PEL progression in vivo. (A-C) NOD/SCID mice were injected i.p. with 107 BCBL-1 cells. Beginning 24 hours later, 20 mg/kg PF-2341066 or vehicle (n = 10 per group) were administered i.p., once daily, 5 days per week, for each of 2 independent experiments. Weights were recorded weekly. Images of representative animals and their spleens, as well as ascites fluid volumes, were collected at the conclusion of experiments on day 35. (D-E) Spleens from representative vehicle- or PF-2341066–treated mice were prepared for routine hematoxylin-and-eosin or immunohistochemistry staining. (F-H) NOD/SCID mice were injected i.p. with 107 BCBL-1 cells. Beginning 28 days later, 20 mg/kg PF-2341066 or vehicle (n = 10 per group) were administered i.p., once daily, 5 days per week. Images of representative animals and their spleens, as well as ascites fluid volumes, were collected at the conclusion of experiments on day 49. Error bars represent the S.E.M. for 1 of 2 independent experiments; *P < .01.
